Delivery Order SPE2DB20D9223-SPE2DB25FV82J
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $8,339.18 by the Defense Logistics Agency (DLA) on July 24, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The contract is a firm fixed-price delivery order with an ultimate completion date of July 25, 2025, and carries no set-aside designation. This award was issued under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,339.18 by the Defense Logistics Agency on July 21, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This delivery order was issued without a set-aside designation and is scheduled for completion by July 22, 2025, with performance taking place at the contractor's Park Ridge facility. The award represents a...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a delivery order award from the Defense Logistics Agency (DLA) on July 22, 2025, for 60 tablets of Xtandi 80 mg, a prescription medication commonly used in oncology treatment. The delivery order, valued at $4,169.59 with firm fixed pricing, is expected to be completed by July 23, 2025. This award carries no set-aside designation and represents a direct distribution of...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a $4,311.35 firm fixed-price delivery order from the Defense Logistics Agency (DLA) on July 18, 2025, for 120 capsules of Xtandi 40 mg. The delivery order is not designated as a set-aside contract and carries an ultimate completion date of July 21, 2025. This award represents a single delivery transaction executed under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,311.35 by the Defense Logistics Agency on July 18, 2025, for the supply of Xtandi 40 mg capsules (120-count). The delivery order carries an ultimate completion date of July 21, 2025, and does not utilize a set-aside designation. This award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $8,339.18 by the Defense Logistics Agency on July 28, 2025, for the supply of Xtandi 80 mg tablets (60-count packages). This firm fixed-price delivery order, with an ultimate completion date of July 29, 2025, represents a specific product requisition under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was awarded a delivery order valued at $4,169.59 by the Defense Logistics Agency (DLA) on July 22, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This firm fixed-price delivery order, with an ultimate completion date of July 23, 2025, represents a discrete purchase under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a delivery order award from the Defense Logistics Agency (DLA) on July 21, 2025, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, valued at $4,311.35, is set to be completed by July 22, 2025, and will be performed at the vendor's Park Ridge, Illinois location. The award carries no set-aside designation, allowing DMS...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $25,017.54 on July 21, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The award was issued under a firm fixed-price contract type with no set-aside designation, reflecting the company's competitive standing in federal procurement markets. The funding agency is the Defense Logistics Agency's Medical Supply Chain division, and...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on July 28, 2025, for the supply of Xtandi 40 mg capsules (120-count units) to the Defense Logistics Agency's Medical Supply Chain division. This firm fixed-price delivery order, valued at $4,311.35, represents performance through July 29, 2025, and carries no set-aside designation. The award leverages DMS Pharmaceutical Group's position as a...
- SPE2DB20D9223Indefinite Delivery Contract
- SPE2DB20D9223-SPE2DB25FV82JDelivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on July 28, 2025, valued at $4,169.59 for the supply of Xtandi 40 mg tablets (120 count) to the Defense Logistics Agency (DLA). This firm fixed-price delivery order, which must be completed by July 29, 2025, carries no set-aside designation. The award leverages DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, a $500 million vehicle valid through November 2026 that enables the agency to issue delivery orders for pharmaceutical supplies supporting military health facilities worldwide. As a established supplier within the federal pharmaceutical supply chain since 2001, DMS Pharmaceutical Group specializes in distributing branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare facilities. Xtandi, an oncology medication, aligns with the company's portfolio of specialty pharmaceutical products previously supplied under its DLA contract framework. This delivery order represents one of numerous orders issued under the SPE2DB program, reflecting the DLA's ongoing requirement to maintain a robust inventory of essential medications for military medical operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.2k | 7/28/25 |